Abstract
We sought to validate magnetic resonance imaging (MRI) for documenting the effects of rosiglitazone on rabbit atherosclerosis and the possible mechanism by treatment on the lesions. 24 New Zealand white rabbits were randomly divided into normal group, control group and treatment group. After 4 weeks, all rabbits underwent MRI. After examination, the number of circulating endothelial progenitor cells (EPCs) and level of lipid, glucose, nitric oxide (NO) and superoxide anion (O −2· ) were measured. MRI demonstrated the regression of atherosclerotic lesions by rosiglitazone which has good correlation with histopathology. Treatment not only increased the level of EPCs and NO, but also raised the ability of inhibition of O −2· . MRI is a promising noninvasive technology to detect the effects of therapeutic interventions. Rosiglitazone slows the progression of atherosclerosis that may in part attribute to its improvement of mobilization of EPCs and the reduced oxidative stress.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels [J]. N Engl J Med, 1998, 339(19): 1349–1357.
Helft G, Worthley S G, Fuster V, et al. Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging [J]. Circulation, 2002, 105(8): 993–998.
Chironi G, Walch L, Pernollet M G., et al. Decreased number of circulating CD34+KDR+ cells in asymptomatic subjects with preclinical atherosclerosis [J]. Atherosclerosis, 2007, 191(1): 115–120.
Li A C, Brown K K, Silvestre M J, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptordeficient mice [J]. J Clin Invest, 2000, 106(4): 523–531.
Hwang J, Kleinhenz D J, Rupnow H L, et al. The PPAR-gamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice [J]. Vascul Pharmacol, 2007, 46(6): 456–462.
Pastercamp G, Falk E, Woutman H, et al. Techniques characterizing to the coronary atherosclerotic plaque: influence on clinical decision making? [J]. J Am Coll Cardiol, 2000, 36(1): 13–21.
Corti R, Osende J I, Fallon J T, et al. The selective peroxisomal proliferator-activated receptor-gama agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging [J]. J Am Coll Cardiol, 2004, 43(3): 464–473.
Quirici N, Soligo D, Caneva L, et al. Differentiation and expansion of endothelial cells from human bone marrow CD133+ cells [J]. Br J Haematol, 2001, 115(1): 186–194.
Wang C H, Ting M K, Verma S, et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus [J]. American Heart Journal, 2006, 152(6):e1–e8.
Chen J Z, Zhang F R, Tao Q M, et al. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolemia [J]. Clinical Science, 2004, 107(3): 273–280.
Author information
Authors and Affiliations
Corresponding author
Additional information
Foundation item: the Science and Technology Commission of Shanghai Municipality (No. 05JC14031)
Rights and permissions
About this article
Cite this article
Zhao, Q., Wei, M. & Zhao, Bh. Effects of rosiglitazone on rabbit atherosclerosis. J. Shanghai Jiaotong Univ. (Sci.) 13, 759–762 (2008). https://doi.org/10.1007/s12204-008-0759-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12204-008-0759-3
Key words
- magnetic resonance imaging (MRI)
- atherosclerosis
- rosiglitazone
- endothelial progenitor cells
- oxidative stress